I know it was discussed some previously on ihub, b
Post# of 148278
I am not very familiar with all the requirements involved and seems that a large BP would be much more efficient, albeit at a pretty significant cost. I also know that other companies have struggled trying to go alone.
I know this would not be well received if they attempted such, but could see it paying off if they make it. If leronlimab turns out to work well in many indications, I could see it pretty much selling itself.
I'm not hoping or suggesting I think they will do this, just curious of opinions from those more familiar with such processes if this is even a viable option?